Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX: PBT) covers the month of December 2017. The registrant is a foreign private issuer based in Australia. The filing primarily serves to announce a new issue of unlisted options under the company's Employee Incentive Scheme (ESOP) and to provide the Australian Securities Exchange (ASX) with details regarding the application for quotation of these additional securities.
Key Financial Metrics and Capital Structure
The filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. Instead, it details the following capital structure updates:
- Ordinary Shares on Issue: 533,891,470 fully paid ordinary shares.
- New Securities Issued: 12,100,000 unlisted options.
- Exercise Price: AUD$0.11 per option.
- Expiry Date: 14 December 2022.
- Consideration: Nil cash consideration (issued under ESOP).
- Total Unlisted Options: Following this issue, the total number of unlisted options on issue is 30,426,063.
Material Changes Versus Prior Period
The primary material change reported is the issuance of 12,100,000 new unlisted options on 18 December 2017. This issuance was conducted under an exception in ASX Listing Rule 7.2. The filing notes that security holder approval for the entity's placement capacity was previously obtained on 17 November 2017. No other material changes to the company's operations or financial position are disclosed in this specific document.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or an outlook for future periods. It is a regulatory disclosure regarding a specific capital event. The document notes that the new options rank equally with existing quoted securities upon exercise into ordinary shares. No specific risks or contingencies are detailed beyond the standard regulatory requirements for the issuance.
Important Facts for Investor Verification
- Verify the total number of options outstanding (30,426,063) and the dilution potential upon exercise of the new tranche at AUD$0.11.
- Confirm the remaining placement capacity under ASX Rules 7.1 and 7.1A, which stands at 80,083,721 and 53,389,147 securities respectively, as calculated in Annexure 1.
- Note that the company name in the metadata (Altery Therapeutics) differs from the registrant name in the filing (Prana Biotechnology Limited); verify the current corporate identity and ticker symbol.
- Check subsequent filings for any financial performance data, as this Form 6-K contains no revenue or profit figures.